Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 2, 2017, Pages 466-472

  Gountas, Ilias ^a   Sypsa, Vana ^a   Papatheodoridis, George ^a   Souliotis, George ^b   Razavi, Homie ^c   Hatzakis, Angelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PELOPONNESE   (Greece)

^c Center for Disease Analysis   (United States)

Author keywords

disease burden; elimination; Greece; hepatitis C; modeling; projections

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; GREECE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; VIRAL CLEARANCE; WORLD HEALTH ORGANIZATION; COMBINATION DRUG THERAPY; DISEASE ERADICATION; MASS SCREENING; TIME FACTOR;

ANTIVIRAL AGENTS; DISEASE ERADICATION; DRUG THERAPY, COMBINATION; GREECE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MASS SCREENING; MORBIDITY; POLYETHYLENE GLYCOLS; PREVALENCE; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS; WORLD HEALTH ORGANIZATION;

EID: 85013304687     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13485     Document Type: Article

References (26)

1. Hatzakis A, Wait S, Bruix J et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J. Viral Hepat. 2011; 18 (Suppl 1): 1–16.
2. Mohd Hanafiah K, Groeger J, Flaxman AD et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333–1342.
3. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014; 370: 1594–1603.
4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014; 370: 211–221.
5. WHO. Global Health Sector Strategies for HIV/Viral Hepatitis/Sexually Transmitted Infections, 2016–2021. Volume 2015: WHO, 2015.
6. Papatheodoridis G, Sypsa V, Kantzanou M et al. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. J. Viral Hepat. 2015; 22: 409–415.
7. Sypsa V, Touloumi G, Tassopoulos NC et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J. Viral Hepat. 2004; 11: 366–374.
8. Gane E, Kershenobich D, Seguin-Devaux C et al. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2. J. Viral Hepat. 2015; 22 (Suppl 1): 46–73.
9. Wedemeyer H, Duberg AS, Buti M et al. Strategies to manage hepatitis C virus (HCV) disease burden. J. Viral Hepat. 2014; 21 (Suppl 1): 60–89.
10. Paraskevis D, Nikolopoulos G, Fotiou A et al. Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One 2013; 8: e78941.
11. Hatzakis A, Chulanov V, Gadano AC et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2. J. Viral Hepat. 2015; 22 (Suppl 1): 26–45.
12. Saraswat V, Norris S, de Knegt RJ et al. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2. J. Viral Hepat. 2015; 22 (Suppl 1): 6–25.
13. Razavi H, Elkhoury AC, Elbasha E et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164–2170.
14. Vandijck D, Moreno C, Starkel P et al. Current and future health and economic impact of hepatitis C in Belgium. Acta Gastroenterol. Belg. 2014; 77: 285–290.
15. Starkel P, Vandijck D, Laleman W et al. The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy. Acta Gastroenterol. Belg. 2014; 77: 280–284.
16. Myers RP, Krajden M, Bilodeau M et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can. J. Gastroenterol. Hepatol. 2014; 28: 243–250.
17. Cramp ME, Rosenberg WM, Ryder SD et al. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol. 2014; 14: 137.
18. Duberg AS, Blach S, Falconer K et al. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand. J. Gastroenterol. 2015; 50: 233–244.
19. Waked I, Doss W, El-Sayed MH et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J. Gastroenterol. 2014; 15: 45–52.
20. United Nations – Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, and World Population Prospects: The 2010 Revision and World Urbanization Prospects: The 2010 Revision. 2011.
21. Raptopoulou M, Touloumi G, Tzourmakliotis D et al. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia 2011; 15: 26–31.
22. United Nations Statistics Division. 2013. UNSD Demographic Statistics: deaths by age, sex and urban/rural residence.
23. Hickman M, Carnwath Z, Madden P et al. Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J. Urban Health 2003; 80: 274–287.
24. Engstrom A, Adamsson C, Allebeck P et al. Mortality in patients with substance abuse: a follow-up in Stockholm County, 1973-1984. Int. J. Addict. 1991; 26: 91–106.
25. Perucci CA, Davoli M, Rapiti E et al. Mortality of intravenous drug users in Rome: a cohort study. Am. J. Public Health 1991; 81: 1307–1310.
26. Kamper-Jorgensen M, Ahlgren M, Rostgaard K et al. Survival after blood transfusion. Transfusion 2008; 48: 2577–2584.